Search Results

Displaying Results 1-1 of 1 "'SQZ'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Checkpoint Inhibitor Refractory Cancer Market Outlook is Predicted to Improve by 2036, Biopharma Companies Advance Novel Immuno-Oncology Candidates | DelveInsight

Aug 19, 2026, 10:31 ET Checkpoint Inhibitor Refractory Cancer Market Outlook is Predicted to Improve by 2036, Biopharma Companies Advance Novel Immuno-Oncology Candidates | DelveInsight

Laboratories, NATCO Pharma, AstraZeneca, EMD Serono Research & Development Institute, Bristol-Myers Squibb, ImmuneSensor Therapeutics, ImmunityBio, SQZ Biotechnologies, Teon Therapeutics, ALX Oncology, Astellas Pharma, Seagen, Hoffmann-La Roche, NextCure, MiNK Therapeutics, Genmab, BioNTech SE, STORM

More news about: DelveInsight Business Research, LLP

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.